Stable Id Screen title Pubmed Id Entrez Id Author-provided gene Id Assay Biomodel Reagent Id Score type Score cutoff Score Phenotype Comment GR00184-A-1 Self-renewal and pluripotency in human embryonic stem cells (1) 20953172 29088 NM_014175 POU5F1 protein expression hESC H1 M-013052-00 Z-score < -2 -0.29631008687303 none GR00196-A-1 TP53 interactions (1) 21642980 29088 ENSG00000137547 TP53 protein expression and viability HCT116 ( wildtype and TP53 knockout) np Complex, sp Complex criteria sp none GR00151-A-1 Homologous recombination DNA double-strand break repair (HR-DSBR) (1) 20613862 29088 ENSG00000137547 (HR-DSBR) DR-GFP reporter HeLa np Z-score < -2 OR > 2 0.975 none GR00180-A-1 Hepatitis C virus replication (1) 19286138 29088 29088 HCV replicon RNA copy number Huh7/Rep-Feo PL-50057 q-value Complex criteria 0.689 none GR00054-A Combinatorial effect with paclitaxel 17429401 29088 NM_014175 Viability (synthetic lethal) NCI-H1155 np Paclitaxel/control ratio Complex criteria 0.957 none GR00056-A Melanogenesis 19057677 29088 NM_014175 Melanin protein expression and viability MNT-1 np Normalized absorbance ratio > 2 standard deviations below mean 0.881 none GR00098-A-1 Cell division (1) 17994010 29088 ENSG00000137547 Cell number and DNA content HeLa ENSG00000137547 Complex, sp Complex criteria sp none GR00197-A-1 Human papillomavirus oncogene expression regulation (1) 20133580 29088 29088 HPV18 LCR reporter activity C33A/BE2/18LCR c4 M-013052-00 Z-score >= 2 -0.959826796 none GR00053-A Genome stability 19647519 29088 NM_014175 gamma-H2AX phosphorylation and DNA content HeLa np p-value Complex criteria sp none GR00233-A-2 Hepatitis C virus (HCV) infection (2) 19717417 29088 29088 HCV core protein expression and DNA content after direct virus infection Huh7.5.1 D-013052-03 Normalized percentage of infected cells <= 0.5 OR >= 1.5 0.85 none GR00233-A-2 Hepatitis C virus (HCV) infection (2) 19717417 29088 29088 HCV core protein expression and DNA content after direct virus infection Huh7.5.1 D-013052-01 Normalized percentage of infected cells <= 0.5 OR >= 1.5 0.27 Decreased JFH-1 genotype 2a Hepatitis C virus (HCV) infection after direct virus infection GR00233-A-2 Hepatitis C virus (HCV) infection (2) 19717417 29088 29088 HCV core protein expression and DNA content after direct virus infection Huh7.5.1 D-013052-02 Normalized percentage of infected cells <= 0.5 OR >= 1.5 0.47 Decreased JFH-1 genotype 2a Hepatitis C virus (HCV) infection after direct virus infection GR00233-A-2 Hepatitis C virus (HCV) infection (2) 19717417 29088 29088 HCV core protein expression and DNA content after direct virus infection Huh7.5.1 D-013052-04 Normalized percentage of infected cells <= 0.5 OR >= 1.5 0.38 Decreased JFH-1 genotype 2a Hepatitis C virus (HCV) infection after direct virus infection GR00233-A-3 Hepatitis C virus (HCV) infection (3) 19717417 29088 29088 HCV core protein expression and DNA content after viral supernatant infection Huh7.5.1 D-013052-03 Normalized percentage of infected cells <= 0.5 OR >= 1.5 0.29 Decreased JFH-1 genotype 2a Hepatitis C virus (HCV) infection after viral supernatant infection GR00233-A-3 Hepatitis C virus (HCV) infection (3) 19717417 29088 29088 HCV core protein expression and DNA content after viral supernatant infection Huh7.5.1 D-013052-01 Normalized percentage of infected cells <= 0.5 OR >= 1.5 0.14 Decreased JFH-1 genotype 2a Hepatitis C virus (HCV) infection after viral supernatant infection GR00233-A-3 Hepatitis C virus (HCV) infection (3) 19717417 29088 29088 HCV core protein expression and DNA content after viral supernatant infection Huh7.5.1 D-013052-02 Normalized percentage of infected cells <= 0.5 OR >= 1.5 0.38 Decreased JFH-1 genotype 2a Hepatitis C virus (HCV) infection after viral supernatant infection GR00233-A-3 Hepatitis C virus (HCV) infection (3) 19717417 29088 29088 HCV core protein expression and DNA content after viral supernatant infection Huh7.5.1 D-013052-04 Normalized percentage of infected cells <= 0.5 OR >= 1.5 0.23 Decreased JFH-1 genotype 2a Hepatitis C virus (HCV) infection after viral supernatant infection GR00233-A-1 Hepatitis C virus (HCV) infection (1) 19717417 29088 29088 HCV core protein expression and DNA content after virus infection Huh7.5.1 np Percentage of infected cells <= 50 % OR >= 150 % np Decreased JFH-1 genotype 2a Hepatitis C virus (HCV) infection siRNA pool validated GR00236-A-1 Homologous recombination DNA double-strand break repair (HR-DSBR) (1) 22344029 29088 29088 (HR-DSBR) DR-GFP reporter and DNA content DR-U2OS M-013052-00 Relative HR ratio < ~0.4 OR > 1.88 0.71555734833039 none GR00240-S-1 TRAIL-induced apoptosis (1) 24442637 29088 NM_014175 Viability U251MG M-013052-00 Z-score > 4 0.28 none GR00240-S-2 TRAIL-induced apoptosis (2) 24442637 29088 NM_014175 Viability (synthetic lethal) U251MG M-013052-00 Differential score > 3.6 AND viability Z-score < 4 -1.24 none Z-score -0.83 GR00242-A-1 Selective autophagy regulation (1) 22020285 29088 NM_014175 Sindbis virus (SIN) capsid SIN-mCherry.capsid and autophagosome GFP–LC3 protein expression HeLa/GFP-LC3 np Z-score Complex criteria sp none GR00247-A-1 Regulation of FOXO1 nuclear localization (1) 21460183 29088 EGFP-FOXO1a protein expression and DNA content U2OS np Complex, sp Complex criteria sp none rank: 10865 GR00249-S Vaccinia virus (VACV) infection 23401514 29088 29088 Vaccinia virus VACV IHD-J/GFP protein expression and DNA content HeLa J-013052-17 Z-score >= 1 OR <= -1.5 0.94788 none number of cells compared to control (%): 73.08 GR00249-S Vaccinia virus (VACV) infection 23401514 29088 29088 Vaccinia virus VACV IHD-J/GFP protein expression and DNA content HeLa M-013052-00 Z-score >= 1 OR <= -1.5 -0.58875 none number of cells compared to control (%): 81.05 GR00249-S Vaccinia virus (VACV) infection 23401514 29088 29088 Vaccinia virus VACV IHD-J/GFP protein expression and DNA content HeLa s26456 Z-score >= 1 OR <= -1.5 0.29905 none number of cells compared to control (%): 98.57 GR00249-S Vaccinia virus (VACV) infection 23401514 29088 29088 Vaccinia virus VACV IHD-J/GFP protein expression and DNA content HeLa s26457 Z-score >= 1 OR <= -1.5 0.85635 none number of cells compared to control (%): 76.55 GR00249-S Vaccinia virus (VACV) infection 23401514 29088 29088 Vaccinia virus VACV IHD-J/GFP protein expression and DNA content HeLa s26458 Z-score >= 1 OR <= -1.5 -0.99427 none number of cells compared to control (%): 86.25 GR00253-A hepcidin regulation 24385536 29088 NM_014175 hepcidin::fluc mRNA expression Huh7 np Z-score >= 1.755 OR <= -1.389 -0.843 none GR00057-A-1 Wnt/beta-catenin pathway regulation (1) 18621708 29088 NM_014175 Wnt pathway reporter HeLa M-013052-00 Z-score > 4 -0.4 none GR00057-A-2 Wnt/beta-catenin pathway regulation (2) 18621708 29088 NM_014175 Wnt pathway reporter HeLa M-013052-00 Complex, SP Complex criteria sp none GR00293-A Combinatorial effect with paclitaxel 24860162 29088 Viability HCC366 np Z-score < -2.5 -0.447 none GR00300-A Combinatorial effect with RAF inhibitor PLX4720 23288408 29088 shRNA abundance A375 TRCN0000183071,TRCN0000152195,TRCN0000183973,TRCN0000178922,TRCN0000150607 Number of shRNAs ranked Top1000 > 2 0 none GR00303-A Clear cell renal cell carcinoma (ccRCC) survival regulation 22362593 29088 NM_014175 Proliferation and Viability VHL-deficient RCC4 np Z-score <= -3 -0.59 none GR00310-A-1 Sindbis virus (SINV) infection (1) 24367265 29088 29088 Sindbis virus (SINV) reporter U2OS np Z-score < -3 OR > 2 -0.65 none GR00312-A NOD2 pathway regulation 23322906 29088 29088 NF-kappaB reporter HEK 293 np Normalized percent inhibition < -20 OR > 60; Inconclusive: < -20 and > 120 % viability OR > 60 and < 70 % viability 63.7 Decreased NF-kappaB reporter expression 81,8% viability GR00313-A TNF-alpha pathway regulation 22733992 29088 NM_014175 NFkappaB pathway reporter HEK293T np Z-score <= -2.5 plus additional filters 0.64 none GR00376-A-1 Mitigators of SS1P-induced immunotoxicity 25713356 29088 29088 Viability KB cells [object Object] RSA P-value <0.001 0.196419072 none GR00376-A-2 Sensitizers of SS1P-induced immunotoxicity 25713356 29088 29088 Viability KB cells [object Object] RSA P-value <0.001 0.142937314 none GR00378-A Poliovirus vaccine production 26581994 29088 Infection with Attenuated Poliovirus HEp-2C [object Object] Z-score >=3 -0.53739409 none GR00378-A Poliovirus vaccine production 26581994 29088 Infection with Attenuated Poliovirus HEp-2C [object Object] Z-score >=3 0.109560919 none GR00381-A-1 Regulation of mammary epithelial cell growth (1) 25572802 29088 NM_014175 Viability 184-hTERT-L9 (mammary epithelial cells) [object Object] Percent growth < 25 % AND p-value < 0.05 55.581 none GR00386-A-1 NOD2 stimulation by MDP 25170077 29088 29088 Viability HEK293 stably expressing NOD2 [object Object] Percentage growth Decreased: <70, increased: >120 76.9189660425044 none GR00386-A-2 MDP-induced IL-8 secretion 25170077 29088 29088 IL-8 secretion HEK293 stably expressing NOD2 [object Object] Percent inhibition of IL-8 secretion Increased: <-300, Decreased: >60 -17 none GR00400-S-1 Combinatorial effect with vorinostat (1) 25977774 29088 29088 Caspase 3/7 activity HCT116 (Vorinostat resistant subclone) M-013052-00 Z-score >=5.13 -0.07 none GR00402-S-1 Host restriction factor for the Mycobacterium tuberculosis infection to A549 cells (1) 29088 29088 The percentage of infected cells A549 SIR0010629 Z-score > 5 -3.535583018593687 no effect 5 days post-infection GR00402-S-2 Host restriction factor for the Mycobacterium tuberculosis infection to A549 cells (2) 29088 29088 The percentage of infected cells A549 SIR0010629 Z-score > -3 -6.556193681469293 Decreased viability 5 days post-infection